Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Novel HCV NS3 protease inhibitors under study at BMS

Aug. 6, 2003

Chiron licenses HCV technology to Gilead for drug development efforts

Aug. 6, 2003

Probactrix controls HIV-associated diarrhea in clinical trial

Aug. 4, 2003

FDA approval for Rebetol in pediatric hepatitis C

Aug. 4, 2003

Enrollment completed in phase II trial of Ceplene in hepatitis C nonresponders

July 31, 2003

Beneficial effects found for EGF enema and oral mesalamine in ulcerative colitis

July 31, 2003

CPMP recommends approval of Remicade for maintenance dosing in fistulizing CD

July 30, 2003

Phase III induction trial of Antegren fails to meet primary endpoint

July 29, 2003

Pfizer claims new 5-HT4 receptor modulators and their use in gastrointestinal disorders

July 28, 2003

Spotlight on viral enzyme inhibitors for the treatment of chronic hepatitis B

July 28, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...